Top Microbubbles/Ultrasound Contrast Agents Companies

Global Microbubbles/Ultrasound Contrast Agents Market size was valued at USD 2.62 Billion in 2024 and is poised to grow from USD 2.74 Billion in 2025 to USD 3.93 Billion by 2033, growing at a CAGR of 4.6% during the forecast period (2026–2033). 

The major players covered in the microbubble contrast media market , while GE Healthcare is committed to providing a broad comprehensive portfolio of CM products that help meet your patient and procedural needs across a multitude of modalities. 'Bracco Imaging S.p.A. (Italy) ', 'GE Healthcare (USA) ', 'Lantheus Holdings, Inc. (USA) ', 'FUJIFILM VisualSonics, Inc. (Canada) ', 'Siemens Healthineers AG (Germany) ', 'Canon Medical Systems Corporation (Japan) ', 'Samsung Medison Co., Ltd. (South Korea) ', 'Mindray Bio-Medical Electronics Co., Ltd. (China) ', 'Philips Healthcare (Netherlands) ', 'Advanced Microbubbles Laboratories B.V. (Netherlands) ', 'Targeson, Inc. (USA) ', 'VisualSonics (Canada) ', 'NanoMedical Diagnostics, Inc. (USA) ', 'Medtron AG (Germany) ', 'Insightec Ltd. (Israel) ', 'SuperSonic Imagine S.A. (France) ', 'Telemed Ultrasound Systems (Lithuania)'

The use of microbubbles and ultrasound contrast agents in molecular imaging is further driven by the growing demand for targeted therapies and the need to monitor the status of the biomarker in the vascular endothelium. During the forecast period, the microbubbles/ultrasound contrast agents market is anticipated to expand due to advancements in ultrasound technologies, an increase in the demand for targeted diagnostic tools, the advantages of microbubbles/ultrasound contrast agents over traditional diagnostic tools, and an increase in the prevalence of chronic diseases.

In cardiology and radiology, microbubbles are utilized as blood-pool agents for contrast ultrasound imaging. They are now being recognized for their potential as targeted agents for molecular imaging. Using ligand molecules that bind to disease-related molecular markers, microbubbles can be made functional. Monitoring the biomarker status of vascular endothelium, visualizing tumor vasculature, and imaging inflammation and ischemia-reperfusion injury zones and thrombi are all potential clinical applications of molecular imaging with microbubble-based ultrasound contrast agents.

Europe is anticipated to be dominant in the microbubbles/ultrasound contrast agents market. The growth of the global microbubbles/ultrasound contrast agents market in North America and Europe is driven by an increase in the geriatric population, an increase in the incidence and prevalence of chronic diseases, a well-established healthcare infrastructure, an increase in the cost of research and development, an increase in the adoption of advanced technologies, and higher healthcare expenditure in the regions. India and China are expected to dominate the microbubbles/ultrasound contrast agents market in Asia-Pacific during the forecast period due to their large patient bases, rising awareness, increased government efforts to improve public health, and developed healthcare infrastructure. Due to the increasing investments made by market participants in these regions, it is anticipated that the global market for microbubbles/ultrasound contrast agents will expand during the forecast period.